首页工具

购物车

Indolidan

产品编号 T32160 CAS 100643-96-7

别名: LY 195115

Indolidan (LY 195115) 诱导费舍尔344大鼠的心血管和肾上腺增生性病变。 Indolidan 可增加心血管疾病的风险。

TargetMol的所有产品仅用作科学研究或药证申报，不能被用于人体，我们不向个人提供产品和服务。请您遵守承诺用途，不得违反法律法规规定用于任何其他用途。

Indolidan, CAS 100643-96-7

规格	价格/CNY	货期
1 mg	￥ 1,120	现货
5 mg	￥ 2,760	现货
10 mg	￥ 3,970	现货
25 mg	￥ 6,560	现货
50 mg	￥ 8,930	现货
100 mg	￥ 11,800	现货
500 mg	￥ 23,900	现货

大包装超大折扣，点击咨询

选择批次

纯度: 99.60%

纯度: 99.51%

更多批次查询请联系客服

生物活性

化学信息

存储 & 溶解度

参考文献

产品描述

Indolidan (LY 195115) induces cardiovascular and adrenal hyperplastic lesions in Fischer 344 rats. Indolidan increases the risk of cardiovascular disease.

体内活性

Male and female Fischer 344 rats were treated with the positive inotropic agents, isomazole or indolidan, in the diet for 104 weeks. The doses were 0.0, 11.5, 23.5, or 48.0 mg/kg and 0.0, 0.12, 0.40, or 1.3 mg/kg, respectively. Only 17% of the males treated with 48.0 mg/kg isomazole survived the duration of the study. The male component of the indolidan study was terminated at 22 months, with only 18% of the high-dose males surviving. Sixty-five percent of the males treated with 48.0 mg/kg isomazole and 70% of the males treated with 1.3 mg/kg indolidan were found to have severe periarteritis, often with thrombi located mainly in the mesenteric arteries. Fifty-four percent of the male rats treated with 48.0 mg/kg isomazole and 55% of the male rats treated with 1.3 mg/kg indolidan died from cardiovascular disease compared to 1-2% among the control males. Animals in the low- and middle-dose groups of both studies had a lower incidence of cardiovascular disease than did those in the high-dose group. Additional lesions associated with the long-term administration of both drugs were markedly increased incidence of adrenal medullary proliferative lesions (both hyperplasia and pheochromocytomas) and increased incidence of chronic progressive glomerulonephrosis. These lesions, like those in the cardiovascular system, occurred in a dose-dependent manner and were more frequent in males than in females.[5]

别名	LY 195115
分子量	257.29
分子式	C14H15N3O2
CAS No.	100643-96-7

存储

Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度

DMSO: 5.63 mg/mL (21.86 mM), Sonication is recommended.

溶液配制表

可选溶剂	浓度体积质量	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.8867 mL	19.4333 mL	38.8666 mL	97.1666 mL
	5 mM	0.7773 mL	3.8867 mL	7.7733 mL	19.4333 mL
	10 mM	0.3887 mL	1.9433 mL	3.8867 mL	9.7167 mL
	20 mM	0.1943 mL	0.9717 mL	1.9433 mL	4.8583 mL

计算器

摩尔浓度计算器

稀释计算器

配液计算器

分子量计算器

质量

浓度

容积

分子量

浓度 (起始)

容积 (起始)

浓度 (终)

容积 (终)

溶液体积

质量

配液浓度

参考文献

1. Haynes J Jr, et al. 5-(N-ethylcarboxamido)adenosine desensitizes the A2b-adenosine receptor in lung circulation. Am J Physiol. 1999;276(6):1877-1883. 2. Naka Y, et al. cAMP-mediated vascular protection in an orthotopic rat lung transplant model. Insights into the mechanism of action of prostaglandin E1 to improve lung preservation. Circ Res. 1996;79(4):773-783. 3. Ashikaga T, et al. Comparison of indolidan analog binding sites of drug antibody and sarcoplasmic reticulum with inhibition of cyclic AMP phosphodiesterase. J Recept Signal Transduct Res. 1996;16(5-6):315-337. 4. Rousseau E, et al. Specific cyclic nucleotide phosphodiesterase inhibitors differently modulate contractile kinetics in airway smooth muscle. Can J Physiol Pharmacol. 1995;73(12):1784-1794. 5. Sandusky GE Jr, et al. Cardiovascular and adrenal proliferative lesions in Fischer 344 rats induced by long-term treatment with type III phosphodiesterase inhibitors (positive inotropic agents), isomazole and indolidan. Fundam Appl Toxicol. 1991;16(1):198-209. 6. Corder CN, et al. Clinical effect of indolidan in congestive heart failure. Int J Clin Pharmacol Ther Toxicol. 1992;30(10):405-409.

剂量换算

对于不同动物的给药剂量换算，您也可以参考 更多...

体内实验配液计算器

请在以下方框中输入您的动物实验信息后点击计算，可以得到母液配置方法和体内配方的制备方法：比如您的给药剂量是10 mg/kg，每只动物体重20 g，给药体积100 μL，一共给药动物10 只，您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。

母液配置方法：2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL)，如您需要配置的浓度超过该产品的溶解度，请先与我们联系。

体内配方的制备方法：取 50 μL DMSO 主液，加入 300 μL PEG300，混匀澄清，再加 50 μL Tween 80，混匀澄清，再加 600 μL ddH2O, 混匀澄清。

第一步：请输入动物实验的基本信息

剂量

mg/kg

每只动物体重

给药体积

μL

动物数量

第二步：请输入动物体内配方组成，不同的产品配方组成不同，如有配方需求，可先联系我们提供正确的体内配方。

% DMSO+

% +